多巴胺
多巴胺能
医学
药理学
耐受性
运动障碍
加药
疾病
益生菌
神经科学
运动协调
左旋多巴
运动活动
帕金森病
转子性能试验
治疗方法
生物信息学
遗传增强
运动行为
体内
口服
肠-脑轴
啮齿动物模型
临床前试验
神经递质
镇静
药代动力学
动物模型
治疗效果
作者
Ahmed Abdalla,Piyush Padhi,Nicholas Backes,Ross T Thyer,Gary D. Zenitsky,Huajun Jin,Vellareddy Anantharam,Arthi Kanthasamy,Andrew D. Ellington,Gregory J. Phillips,Anumantha G. Kanthasamy
标识
DOI:10.1021/acssynbio.5c00786
摘要
High Resolution Image Download MS PowerPoint Slide Dopamine deficiency resulting from nigrostriatal dopaminergic neuronal damage manifests as extrapyramidal motor symptoms of Parkinson’s disease (PD). Oral tablet dosing of levodopa, administered 3–4 times a day, remains the standard of care due to its tolerability and effectiveness; however, it is prone to deleterious side effects, including off-periods and levodopa-induced dyskinesia after long-term use. Herein, using synthetic biology approaches, we developed and systematically evaluated the feasibility of a probiotic-based live-biotherapeutic system to continuously deliver L-DOPA stably, thereby relieving motor symptoms. Our data demonstrate that our engineered plasmid-based L-DOPA-expressing Escherichia coli Nissle 1917 probiotic strain (EcN 2 LDOPA-P3 ) efficiently produced up to 12,000 ng/mL L-DOPA in vitro. In mouse model systems, EcN 2 LDOPA-P3 readily colonized for up to 48 h, achieved steady-state plasma L-DOPA concentrations, and increased brain L-DOPA and dopamine levels by 1- to 2-fold. Lastly, EcN 2 LDOPA-P3 significantly diminished motor and nonmotor behavioral deficits in a mouse model of PD compared to traditional chemical L-DOPA therapy. These findings support the therapeutic feasibility of a noninvasive, orally administered bioengineered bacterial therapy for the chronic delivery of L-DOPA, which may address limitations associated with current treatment alternatives.
科研通智能强力驱动
Strongly Powered by AbleSci AI